Celiac Disease
Conditions
Keywords
celiac disease, tolerance
Brief summary
The goal of this clinical trial is to learn about the safety and the pharmacodynamic (PD) effects of TPM502 in adults with celiac disease. The main questions it aims to answer are: * if TPM502 is safe and well tolerated * if TPM502 can induce modifications in parameters indicating that it may induce tolerance to gluten Participants will: * undergo 1-day gluten challenge during screening and after administration of TPM502 or placebo. * receive 2 infusions of TPM502 or placebo, 2 weeks apart
Detailed description
This is a multi center, double-blind, randomized, placebo-controlled Phase 2a study to evaluate the safety, tolerability, and PD effects of two infusions of TPM502 in adult patients diagnosed with CeD. The patient´s participation in the study comprises 3 phases: screening period, treatment period and follow-up period. Patients fulfilling the eligibility criteria will be randomized to receive two infusions of TMP502 (or placebo) at the same dose level. Patients will undergo a second GC one week after the second infusion of TPM502. The study includes 4 cohorts of patients, each cohort will receive escalating doses of TPM502 (or placebo). Upon completion of the 3rd cohort, a lower dose can be investigated, if deemed relevant.
Interventions
DRUGTPM502
TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
OTHERPlacebo
Placebo
Sponsors
Topas Therapeutics GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Availability of a documented biopsy-confirmed diagnosis of CeD OR documented tissue transglutaminase \>10x ULN and documented positive IgA anti-endomysial antibody (EMA) at time of CeD diagnosis (as per local guidelines) * Serum anti-tissue transglutaminase 2 immunoglobin A antibodies within normal range (i.e., \<15 U/mL) at screening * Serum IL-2 levels (AUC1-6h) above a pre-defined threshold following the GC at screening * Patients must have been on GFD for ≥ 6 months * Patients must have well-controlled CeD, defined as mild or with no ongoing signs or symptoms felt to be related to active CeD, as per investigator's assessment * HLA-DQ2.5 positive
Exclusion criteria
* Known or suspected refractory CeD (refractory CeD type I or II) * Known intolerable symptoms following previous GCs, as per investigator's assessment * HLA DQ8 positive * Any active gastrointestinal disease such as gastroesophageal reflux disease, esophagitis or peptic ulcer, microscopic colitis, or irritable bowel syndrome, which in the opinion of the investigator might interfere with the assessment of the symptoms related to CeD * Known history of or active Crohn's disease, ulcerative colitis, or ulcerative jejunitis * Known wheat allergy * Known hypersensitivity to i.v. iron preparations or any other excipients present in the reconstituted TPM502 or placebo
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence, severity, causality, and outcomes of treatment-emergent adverse events | throughout the study, on average 43 days |
Countries
Australia, Finland, Germany, Netherlands, Norway, Sweden
Outcome results
None listed